{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:26:41Z","timestamp":1792873601478,"version":"4.5.0"},"reference-count":267,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PLL-192128"],"award-info":[{"award-number":["PLL-192128"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010090","name":"Women & Children's Health Research Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010090","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"DOI":"10.1186\/s11658-026-00907-x","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:05:42Z","timestamp":1774962342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeting mutant p53 in cancer: from mechanistic insights to therapeutic strategies"],"prefix":"10.1186","volume":"31","author":[{"given":"H. Helena","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Eisenstat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consolato","family":"Sergi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"907_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","volume":"88","author":"AJ Levine","year":"1997","unstructured":"Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323\u201331.","journal-title":"Cell"},{"key":"907_CR2","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrc2723","volume":"9","author":"AJ Levine","year":"2009","unstructured":"Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009;9:749\u201358.","journal-title":"Nat Rev Cancer"},{"key":"907_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/35042675","volume":"408","author":"B Vogelstein","year":"2000","unstructured":"Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307\u201310.","journal-title":"Nature"},{"key":"907_CR4","doi-asserted-by":"publisher","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","volume":"2","author":"M Olivier","year":"2010","unstructured":"Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2:a001008.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"907_CR5","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin X, et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 2022;13:974.","journal-title":"Cell Death Dis"},{"key":"907_CR6","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.omtn.2023.02.002","volume":"31","author":"HH Wu","year":"2023","unstructured":"Wu HH, Leng S, Abuetabh Y, Sergi C, Eisenstat DD, Leng R. The SWIB\/MDM2 motif of UBE4B activates the p53 pathway. Mol Ther Nucleic Acids. 2023;31:466\u201381.","journal-title":"Mol Ther Nucleic Acids"},{"key":"907_CR7","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/s12276-022-00863-4","volume":"54","author":"Y Abuetabh","year":"2022","unstructured":"Abuetabh Y, Wu HH, Chai C, Al Yousef H, Persad S, Sergi CM, et al. DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities. Exp Mol Med. 2022;54:1658\u201369.","journal-title":"Exp Mol Med"},{"key":"907_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nm.2283","volume":"17","author":"H Wu","year":"2011","unstructured":"Wu H, Pomeroy SL, Ferreira M, Teider N, Mariani J, Nakayama KI, et al. UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. Nat Med. 2011;17:347\u201355.","journal-title":"Nat Med"},{"key":"907_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41418-024-01391-6","volume":"32","author":"AC Joerger","year":"2025","unstructured":"Joerger AC, Stiewe T, Soussi T. TP53: the unluckiest of genes? Cell Death Differ. 2025;32:219\u201324.","journal-title":"Cell Death Differ"},{"key":"907_CR10","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1101\/gad.190678.112","volume":"26","author":"WA Freed-Pastor","year":"2012","unstructured":"Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26:1268\u201386.","journal-title":"Genes Dev"},{"key":"907_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/cdd.2017.180","volume":"25","author":"EH Baugh","year":"2018","unstructured":"Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ. 2018;25:154\u201360.","journal-title":"Cell Death Differ"},{"key":"907_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1126\/science.aax3649","volume":"365","author":"S Boettcher","year":"2019","unstructured":"Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019;365:599\u2013604.","journal-title":"Science"},{"key":"907_CR13","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/s41418-022-00980-7","volume":"29","author":"D Hoyos","year":"2022","unstructured":"Hoyos D, Greenbaum B, Levine AJ. The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein. Cell Death Differ. 2022;29:938\u201345.","journal-title":"Cell Death Differ"},{"key":"907_CR14","doi-asserted-by":"publisher","first-page":"8424","DOI":"10.1073\/pnas.1431692100","volume":"100","author":"S Kato","year":"2003","unstructured":"Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A. 2003;100:8424\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"907_CR15","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1158\/0008-5472.CAN-24-1136","volume":"85","author":"N Klemm","year":"2025","unstructured":"Klemm N, Schimmer RR, Konrad NK, Thelen F, Fullin J, Topcu E, et al. The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect. Cancer Res. 2025;85:1978\u201396.","journal-title":"Cancer Res"},{"key":"907_CR16","doi-asserted-by":"crossref","unstructured":"Chiang YT, Chien YC, Lin YH, Wu HH, Lee DF, Yu YL. The Function of the Mutant p53-R175H in Cancer. Cancers (Basel) 2021;13.","DOI":"10.3390\/cancers13164088"},{"key":"907_CR17","doi-asserted-by":"crossref","unstructured":"Lepre MG, Omar SI, Grasso G, Morbiducci U, Deriu MA, Tuszynski JA. Insights into the Effect of the G245S Single Point Mutation on the Structure of p53 and the Binding of the Protein to DNA. Molecules 2017;22.","DOI":"10.3390\/molecules22081358"},{"key":"907_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2220\/biomedres.40.37","volume":"40","author":"S Nakazawa","year":"2019","unstructured":"Nakazawa S, Sakata KI, Liang S, Yoshikawa K, Iizasa H, Tada M, et al. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells. Biomed Res. 2019;40:37\u201349.","journal-title":"Biomed Res"},{"key":"907_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/jmcb\/mjy086","volume":"11","author":"H Wang","year":"2019","unstructured":"Wang H, Liao P, Zeng SX, Lu H. It takes a team: a gain-of-function story of p53-R249S. J Mol Cell Biol. 2019;11:277\u201383.","journal-title":"J Mol Cell Biol"},{"key":"907_CR20","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1158\/1541-7786.MCR-22-0133","volume":"20","author":"D Lundine","year":"2022","unstructured":"Lundine D, Annor GK, Chavez V, Maimos S, Syed Z, Jiang S, et al. The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose. Mol Cancer Res. 2022;20:1799\u2013810.","journal-title":"Mol Cancer Res"},{"key":"907_CR21","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1038\/oncsis.2016.8","volume":"5","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Coillie SV, Fang JY, Xu J. Gain of function of mutant p53: R282W on the peak? Oncogenesis. 2016;5:e196.","journal-title":"Oncogenesis"},{"key":"907_CR22","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/s41419-022-05431-2","volume":"13","author":"M Palomar-Siles","year":"2022","unstructured":"Palomar-Siles M, Heldin A, Zhang M, Strandgren C, Yurevych V, van Dinter JT, et al. Translational readthrough of nonsense mutant TP53 by mRNA incorporation of 5-Fluorouridine. Cell Death Dis. 2022;13:997.","journal-title":"Cell Death Dis"},{"key":"907_CR23","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/ng.2532","volume":"45","author":"L Holmfeldt","year":"2013","unstructured":"Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45:242\u201352.","journal-title":"Nat Genet"},{"key":"907_CR24","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1093\/hmg\/ddx165","volume":"26","author":"Y Zerdoumi","year":"2017","unstructured":"Zerdoumi Y, Lanos R, Raad S, Flaman JM, Bougeard G, Frebourg T, et al. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage. Hum Mol Genet. 2017;26:2812.","journal-title":"Hum Mol Genet"},{"key":"907_CR25","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1158\/1541-7786.MCR-20-0691","volume":"19","author":"DR Tong","year":"2021","unstructured":"Tong DR, Zhou W, Katz C, Regunath K, Venkatesh D, Ihuegbu C, et al. p53 Frameshift Mutations Couple Loss-of-Function with Unique Neomorphic Activities. Mol Cancer Res. 2021;19:1522\u201333.","journal-title":"Mol Cancer Res"},{"key":"907_CR26","doi-asserted-by":"crossref","unstructured":"Garziera M, Cecchin E, Giorda G, Sorio R, Scalone S, De Mattia E et al. Clonal Evolution of TP53 c.375\u2009+\u20091G\u2009>\u2009A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC). Cells 2019;8.","DOI":"10.3390\/cells8101186"},{"key":"907_CR27","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/cncr.28507","volume":"120","author":"S Hettmer","year":"2014","unstructured":"Hettmer S, Archer NM, Somers GR, Novokmet A, Wagers AJ, Diller L, et al. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer. 2014;120:1068\u201375.","journal-title":"Cancer"},{"key":"907_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2159-8290.CD-20-0336","volume":"11","author":"M Chen","year":"2021","unstructured":"Chen M, Chen X, Li S, Pan X, Gong Y, Zheng J, et al. An Epigenetic Mechanism Underlying Chromosome 17p Deletion-Driven Tumorigenesis. Cancer Discov. 2021;11:194\u2013207.","journal-title":"Cancer Discov"},{"key":"907_CR29","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.1038\/s41388-021-01991-3","volume":"40","author":"AJ Levine","year":"2021","unstructured":"Levine AJ. Spontaneous and inherited TP53 genetic alterations. Oncogene. 2021;40:5975\u201383.","journal-title":"Oncogene"},{"key":"907_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/CCO.0000000000000423","volume":"30","author":"A Amadou","year":"2018","unstructured":"Amadou A, Achatz MIW, Hainaut P. Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. Curr Opin Oncol. 2018;30:23\u20139.","journal-title":"Curr Opin Oncol"},{"key":"907_CR31","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","volume":"33","author":"G Bougeard","year":"2015","unstructured":"Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, et al. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol. 2015;33:2345\u201352.","journal-title":"J Clin Oncol"},{"key":"907_CR32","doi-asserted-by":"publisher","first-page":"7727","DOI":"10.18632\/oncotarget.3115","volume":"6","author":"S Ribi","year":"2015","unstructured":"Ribi S, Baumhoer D, Lee K, Edison, Teo AS, Madan B, et al. TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome. Oncotarget. 2015;6:7727\u201340.","journal-title":"Oncotarget"},{"key":"907_CR33","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/j.1460-2075.1990.tb08279.x","volume":"9","author":"JV Gannon","year":"1990","unstructured":"Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 1990;9:1595\u2013602.","journal-title":"EMBO J"},{"key":"907_CR34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther. 2023;8:92.","journal-title":"Signal Transduct Target Ther"},{"key":"907_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc.2017.109","volume":"18","author":"VJN Bykov","year":"2018","unstructured":"Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18:89\u2013102.","journal-title":"Nat Rev Cancer"},{"key":"907_CR36","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1126\/science.8023157","volume":"265","author":"Y Cho","year":"1994","unstructured":"Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994;265:346\u201355.","journal-title":"Science"},{"key":"907_CR37","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.canlet.2015.02.028","volume":"360","author":"H Wang","year":"2015","unstructured":"Wang H, Bao W, Jiang F, Che Q, Chen Z, Wang F, et al. Mutant p53 (p53-R248Q) functions as an oncogene in promoting endometrial cancer by up-regulating REGgamma. Cancer Lett. 2015;360:269\u201379.","journal-title":"Cancer Lett"},{"key":"907_CR38","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.1038\/s41598-019-42220-y","volume":"9","author":"N Allende-Vega","year":"2019","unstructured":"Allende-Vega N, Villalba M. Metabolic stress controls mutant p53 R248Q stability in acute myeloid leukemia cells. Sci Rep. 2019;9:5637.","journal-title":"Sci Rep"},{"key":"907_CR39","first-page":"1168","volume":"54","author":"MB Olszewski","year":"2019","unstructured":"Olszewski MB, Pruszko M, Snaar-Jagalska E, Zylicz A, Zylicz M. Diverse and cancer type\u2013specific roles of the p53 R248Q gain\u2013of\u2013function mutation in cancer migration and invasiveness. Int J Oncol. 2019;54:1168\u201382.","journal-title":"Int J Oncol"},{"key":"907_CR40","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1016\/j.bpj.2022.10.013","volume":"121","author":"L Julian","year":"2022","unstructured":"Julian L, Sang JC, Wu Y, Meisl G, Brelstaff JH, Miller A, et al. Characterization of full-length p53 aggregates and their kinetics of formation. Biophys J. 2022;121:4280\u201398.","journal-title":"Biophys J"},{"key":"907_CR41","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2641","volume":"15","author":"PA Muller","year":"2013","unstructured":"Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15:2\u20138.","journal-title":"Nat Cell Biol"},{"key":"907_CR42","doi-asserted-by":"publisher","first-page":"e1826","DOI":"10.1038\/cddis.2015.191","volume":"6","author":"BS Tan","year":"2015","unstructured":"Tan BS, Tiong KH, Choo HL, Chung FF, Hii LW, Tan SH, et al. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF). Cell Death Dis. 2015;6:e1826.","journal-title":"Cell Death Dis"},{"key":"907_CR43","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s13046-019-1375-9","volume":"38","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Li Y, Sheng J, Wu F, Li K, Huang R, et al. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs. J Exp Clin Cancer Res. 2019;38:379.","journal-title":"J Exp Clin Cancer Res"},{"key":"907_CR44","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1101\/gad.340976.120","volume":"34","author":"J Gencel-Augusto","year":"2020","unstructured":"Gencel-Augusto J, Lozano G. p53 tetramerization: at the center of the dominant-negative effect of mutant p53. Genes Dev. 2020;34:1128\u201346.","journal-title":"Genes Dev"},{"key":"907_CR45","doi-asserted-by":"publisher","first-page":"16176","DOI":"10.1038\/s41598-020-73234-6","volume":"10","author":"E Ly","year":"2020","unstructured":"Ly E, Kugel JF, Goodrich JA. Single molecule studies reveal that p53 tetramers dynamically bind response elements containing one or two half sites. Sci Rep. 2020;10:16176.","journal-title":"Sci Rep"},{"key":"907_CR46","doi-asserted-by":"publisher","first-page":"15497","DOI":"10.1073\/pnas.1311126110","volume":"110","author":"G Gaglia","year":"2013","unstructured":"Gaglia G, Guan Y, Shah JV, Lahav G. Activation and control of p53 tetramerization in individual living cells. Proc Natl Acad Sci U S A. 2013;110:15497\u2013501.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"907_CR47","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1126\/science.7878469","volume":"267","author":"PD Jeffrey","year":"1995","unstructured":"Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 1995;267:1498\u2013502.","journal-title":"Science"},{"key":"907_CR48","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1038\/sj.onc.1207396","volume":"23","author":"A Willis","year":"2004","unstructured":"Willis A, Jung EJ, Wakefield T, Chen X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene. 2004;23:2330\u20138.","journal-title":"Oncogene"},{"key":"907_CR49","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/carcin\/bgaa117","volume":"41","author":"Y Stein","year":"2020","unstructured":"Stein Y, Aloni-Grinstein R, Rotter V. Mutant p53 oncogenicity: dominant-negative or gain-of-function? Carcinogenesis. 2020;41:1635\u201347.","journal-title":"Carcinogenesis"},{"key":"907_CR50","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1158\/0008-5472.CAN-25-1054","volume":"85","author":"J Gencel-Augusto","year":"2025","unstructured":"Gencel-Augusto J, Lozano G. Targeted Degradation of Mutant p53 Reverses the Pro-oncogenic Dominant-Negative Effect. Cancer Res. 2025;85:1955\u20136.","journal-title":"Cancer Res"},{"key":"907_CR51","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","volume":"25","author":"PA Muller","year":"2014","unstructured":"Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25:304\u201317.","journal-title":"Cancer Cell"},{"key":"907_CR52","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.jmb.2017.03.030","volume":"429","author":"X Yue","year":"2017","unstructured":"Yue X, Zhao Y, Xu Y, Zheng M, Feng Z, Hu W. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy. J Mol Biol. 2017;429:1595\u2013606.","journal-title":"J Mol Biol"},{"key":"907_CR53","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41418-023-01253-7","volume":"31","author":"LD Attardi","year":"2024","unstructured":"Attardi LD, Boutelle AM. Targeting p53 gain-of-function activity in cancer therapy: a cautionary tale. Cell Death Differ. 2024;31:133\u20135.","journal-title":"Cell Death Differ"},{"key":"907_CR54","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ccell.2018.07.004","volume":"34","author":"R Schulz-Heddergott","year":"2018","unstructured":"Schulz-Heddergott R, Stark N, Edmunds SJ, Li J, Conradi LC, Bohnenberger H, et al. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. Cancer Cell. 2018;34:298\u2013314. e297.","journal-title":"Cancer Cell"},{"key":"907_CR55","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.molcel.2015.02.015","volume":"57","author":"O Laptenko","year":"2015","unstructured":"Laptenko O, Shiff I, Freed-Pastor W, Zupnick A, Mattia M, Freulich E, et al. The p53 C terminus controls site-specific DNA binding and promotes structural changes within the central DNA binding domain. Mol Cell. 2015;57:1034\u201346.","journal-title":"Mol Cell"},{"key":"907_CR56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/358015a0","volume":"358","author":"DP Lane","year":"1992","unstructured":"Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358:15\u20136.","journal-title":"Nature"},{"key":"907_CR57","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1158\/2159-8290.CD-23-1362","volume":"14","author":"DP Lane","year":"2024","unstructured":"Lane DP. Mutant p53 Gain-of-Function in the Spotlight: Are We Suffering a GOF Delusion? Cancer Discov. 2024;14:211\u20133.","journal-title":"Cancer Discov"},{"key":"907_CR58","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/jmcb\/mjaa040","volume":"12","author":"C Zhang","year":"2020","unstructured":"Zhang C, Liu J, Xu D, Zhang T, Hu W, Feng Z. Gain-of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol. 2020;12:674\u201387.","journal-title":"J Mol Cell Biol"},{"key":"907_CR59","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/humu.23035","volume":"37","author":"L Bouaoun","year":"2016","unstructured":"Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J, et al. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. Hum Mutat. 2016;37:865\u201376.","journal-title":"Hum Mutat"},{"key":"907_CR60","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/0092-8674(91)90384-B","volume":"65","author":"J Milner","year":"1991","unstructured":"Milner J, Medcalf EA. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell. 1991;65:765\u201374.","journal-title":"Cell"},{"key":"907_CR61","doi-asserted-by":"crossref","unstructured":"Brdar A, Osterburg C, Munick P, Machel AC, Rathore R, Osterburg S et al. p53 isoforms have a high aggregation propensity, interact with chaperones and lack binding to p53 interaction partners. Elife 2025;13.","DOI":"10.7554\/eLife.103537.3"},{"key":"907_CR62","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1146\/annurev.biochem.77.060806.091238","volume":"77","author":"AC Joerger","year":"2008","unstructured":"Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annu Rev Biochem. 2008;77:557\u201382.","journal-title":"Annu Rev Biochem"},{"key":"907_CR63","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc2693","volume":"9","author":"R Brosh","year":"2009","unstructured":"Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009;9:701\u201313.","journal-title":"Nat Rev Cancer"},{"key":"907_CR64","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1177\/1947601911413466","volume":"2","author":"D Malkin","year":"2011","unstructured":"Malkin D. Li-fraumeni syndrome. Genes Cancer. 2011;2:475\u201384.","journal-title":"Genes Cancer"},{"key":"907_CR65","doi-asserted-by":"publisher","first-page":"607670","DOI":"10.3389\/fcell.2020.607670","volume":"8","author":"E Alvarado-Ortiz","year":"2020","unstructured":"Alvarado-Ortiz E, de la Cruz-Lopez KG, Becerril-Rico J, Sarabia-Sanchez MA, Ortiz-Sanchez E, Garcia-Carranca A. Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches. Front Cell Dev Biol. 2020;8:607670.","journal-title":"Front Cell Dev Biol"},{"key":"907_CR66","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1158\/2159-8290.CD-24-1638","volume":"15","author":"G Lozano","year":"2025","unstructured":"Lozano G, Prives C, Sabapathy K. Mutant p53 Gain of Function: Why Many See It, Why Some Do Not. Cancer Discov. 2025;15:1099\u2013104.","journal-title":"Cancer Discov"},{"key":"907_CR67","doi-asserted-by":"crossref","unstructured":"Cai BH, Hsu YC, Yeh FY, Lin YR, Lu RY, Yu SJ et al. P63 and P73 Activation in Cancers with p53 Mutation. Biomedicines 2022;10.","DOI":"10.3390\/biomedicines10071490"},{"key":"907_CR68","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s42004-024-01289-x","volume":"7","author":"EC Petronilho","year":"2024","unstructured":"Petronilho EC, de Andrade GC, de Sousa GDS, Almeida FP, Mota MF, Gomes A, et al. Oncogenic p53 triggers amyloid aggregation of p63 and p73 liquid droplets. Commun Chem. 2024;7:207.","journal-title":"Commun Chem"},{"key":"907_CR69","doi-asserted-by":"publisher","first-page":"24259","DOI":"10.1073\/pnas.1913919116","volume":"116","author":"J Zhang","year":"2019","unstructured":"Zhang J, Sun W, Kong X, Zhang Y, Yang HJ, Ren C, et al. Mutant p53 antagonizes p63\/p73-mediated tumor suppression via Notch1. Proc Natl Acad Sci U S A. 2019;116:24259\u201367.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"907_CR70","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1093\/nar\/gkab081","volume":"49","author":"HH Wu","year":"2021","unstructured":"Wu HH, Wang B, Armstrong SR, Abuetabh Y, Leng S, Roa WHY, et al. Hsp70 acts as a fine-switch that controls E3 ligase CHIP-mediated TAp63 and DeltaNp63 ubiquitination and degradation. Nucleic Acids Res. 2021;49:2740\u201358.","journal-title":"Nucleic Acids Res"},{"key":"907_CR71","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41419-022-04854-1","volume":"13","author":"B Wang","year":"2022","unstructured":"Wang B, Wu HH, Abuetabh Y, Leng S, Davidge ST, Flores ER, et al. p63, a key regulator of Ago2, links to the microRNA-144 cluster. Cell Death Dis. 2022;13:397.","journal-title":"Cell Death Dis"},{"key":"907_CR72","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ccr.2006.08.014","volume":"10","author":"MJ Peart","year":"2006","unstructured":"Peart MJ, Prives C. Mutant p53 gain of function: the NF-Y connection. Cancer Cell. 2006;10:173\u20134.","journal-title":"Cancer Cell"},{"key":"907_CR73","doi-asserted-by":"crossref","unstructured":"Eriksson M, Ambroise G, Ouchida AT, Lima Queiroz A, Smith D, Gimenez-Cassina A et al. Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism. Mol Cell Biol 2017;37.","DOI":"10.1128\/MCB.00328-17"},{"key":"907_CR74","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/jmcb\/mjy070","volume":"11","author":"J Liu","year":"2019","unstructured":"Liu J, Zhang C, Hu W, Feng Z. Tumor suppressor p53 and metabolism. J Mol Cell Biol. 2019;11:284\u201392.","journal-title":"J Mol Cell Biol"},{"key":"907_CR75","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jare.2024.10.026","volume":"75","author":"X Wang","year":"2025","unstructured":"Wang X, Yang J, Yang W, Sheng H, Jia B, Cheng P, et al. Multiple roles of p53 in cancer development: Regulation of tumor microenvironment, m(6)A modification and diverse cell death mechanisms. J Adv Res. 2025;75:539\u201360.","journal-title":"J Adv Res"},{"key":"907_CR76","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/jcb.23400","volume":"113","author":"W Hanel","year":"2012","unstructured":"Hanel W, Moll UM. Links between mutant p53 and genomic instability. J Cell Biochem. 2012;113:433\u20139.","journal-title":"J Cell Biochem"},{"key":"907_CR77","doi-asserted-by":"crossref","unstructured":"Hertel A, Storchova Z. The Role of p53 Mutations in Early and Late Response to Mitotic Aberrations. Biomolecules 2025;15.","DOI":"10.3390\/biom15020244"},{"key":"907_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41418-024-01259-9","volume":"32","author":"A Janic","year":"2025","unstructured":"Janic A, Abad E, Amelio I. Decoding p53 tumor suppression: a crosstalk between genomic stability and epigenetic control? Cell Death Differ. 2025;32:1\u20138.","journal-title":"Cell Death Differ"},{"key":"907_CR79","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.trecan.2019.11.004","volume":"6","author":"Q Tang","year":"2020","unstructured":"Tang Q, Su Z, Gu W, Rustgi AK. Mutant p53 on the Path to Metastasis. Trends Cancer. 2020;6:62\u201373.","journal-title":"Trends Cancer"},{"key":"907_CR80","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1083\/jcb.201009059","volume":"192","author":"PA Muller","year":"2011","unstructured":"Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol. 2011;192:209\u201318.","journal-title":"J Cell Biol"},{"key":"907_CR81","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1158\/2159-8290.CD-13-0136","volume":"4","author":"E Powell","year":"2014","unstructured":"Powell E, Piwnica-Worms D, Piwnica-Worms H. Contribution of p53 to metastasis. Cancer Discov. 2014;4:405\u201314.","journal-title":"Cancer Discov"},{"key":"907_CR82","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/cdd.2013.17","volume":"20","author":"W Hanel","year":"2013","unstructured":"Hanel W, Marchenko N, Xu S, Yu SX, Weng W, Moll U. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ. 2013;20:898\u2013909.","journal-title":"Cell Death Differ"},{"key":"907_CR83","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2004.11.004","volume":"119","author":"KP Olive","year":"2004","unstructured":"Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119:847\u201360.","journal-title":"Cell"},{"key":"907_CR84","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cell.2009.01.039","volume":"137","author":"M Adorno","year":"2009","unstructured":"Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, et al. A Mutant-p53\/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell. 2009;137:87\u201398.","journal-title":"Cell"},{"key":"907_CR85","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/387296a0","volume":"387","author":"Y Haupt","year":"1997","unstructured":"Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296\u20139.","journal-title":"Nature"},{"key":"907_CR86","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/387299a0","volume":"387","author":"MH Kubbutat","year":"1997","unstructured":"Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387:299\u2013303.","journal-title":"Nature"},{"key":"907_CR87","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/378206a0","volume":"378","author":"SN Jones","year":"1995","unstructured":"Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995;378:206\u20138.","journal-title":"Nature"},{"key":"907_CR88","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/378203a0","volume":"378","author":"R Montes de Oca Luna","year":"1995","unstructured":"Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995;378:203\u20136.","journal-title":"Nature"},{"key":"907_CR89","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1126\/science.1091362","volume":"302","author":"M Li","year":"2003","unstructured":"Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science. 2003;302:1972\u20135.","journal-title":"Science"},{"key":"907_CR90","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.1002\/j.1460-2075.1996.tb00919.x","volume":"15","author":"A Shvarts","year":"1996","unstructured":"Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 1996;15:5349\u201357.","journal-title":"EMBO J"},{"key":"907_CR91","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/sj.cdd.4401912","volume":"13","author":"JC Marine","year":"2006","unstructured":"Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ. 2006;13:927\u201334.","journal-title":"Cell Death Differ"},{"key":"907_CR92","first-page":"3221","volume":"62","author":"RA Finch","year":"2002","unstructured":"Finch RA, Donoviel DB, Potter D, Shi M, Fan A, Freed DD, et al. mdmx is a negative regulator of p53 activity in vivo. Cancer Res. 2002;62:3221\u20135.","journal-title":"Cancer Res"},{"key":"907_CR93","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/ng714","volume":"29","author":"J Parant","year":"2001","unstructured":"Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet. 2001;29:92\u20135.","journal-title":"Nat Genet"},{"key":"907_CR94","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S0092-8674(03)00193-4","volume":"112","author":"R Leng","year":"2003","unstructured":"Leng R, Lin Y, Ma W, Wu H, Lemmers B, Chung S, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell. 2003;112:779\u201391.","journal-title":"Cell"},{"key":"907_CR95","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1158\/1541-7786.MCR-11-0157","volume":"9","author":"H Wu","year":"2011","unstructured":"Wu H, Zeinab RA, Flores ER, Leng R. Pirh2, a ubiquitin E3 ligase, inhibits p73 transcriptional activity by promoting its ubiquitination. Mol Cancer Res. 2011;9:1780\u201390.","journal-title":"Mol Cancer Res"},{"key":"907_CR96","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/carcin\/bgab009","volume":"42","author":"R Abou Zeinab","year":"2021","unstructured":"Abou Zeinab R, Wu HH, Abuetabh Y, Leng S, Sergi C, Eisenstat DD, et al. Pirh2, an E3 ligase, regulates the AIP4-p73 regulatory pathway by modulating AIP4 expression and ubiquitination. Carcinogenesis. 2021;42:650\u201362.","journal-title":"Carcinogenesis"},{"key":"907_CR97","doi-asserted-by":"publisher","first-page":"e1002360","DOI":"10.1371\/journal.pgen.1002360","volume":"7","author":"A Hakem","year":"2011","unstructured":"Hakem A, Bohgaki M, Lemmers B, Tai E, Salmena L, Matysiak-Zablocki E, et al. Role of Pirh2 in mediating the regulation of p53 and c-Myc. PLoS Genet. 2011;7:e1002360.","journal-title":"PLoS Genet"},{"key":"907_CR98","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1186\/s12885-021-08765-w","volume":"21","author":"C Shi","year":"2021","unstructured":"Shi C, Liu S, Tian X, Wang X, Gao P. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma. BMC Cancer. 2021;21:1035.","journal-title":"BMC Cancer"},{"key":"907_CR99","doi-asserted-by":"publisher","first-page":"102226","DOI":"10.1016\/j.clgc.2024.102226","volume":"22","author":"MM Maddah","year":"2024","unstructured":"Maddah MM, Hedayatizadeh-Omran A, Moosazadeh M, Alizadeh-Navaei R. Evaluation of the Prognostic Role of TP53 Gene Mutations in Prostate Cancer Outcome: A Systematic Review and Meta-Analysis. Clin Genitourin Cancer. 2024;22:102226.","journal-title":"Clin Genitourin Cancer"},{"key":"907_CR100","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41598-022-05243-6","volume":"12","author":"E Schaafsma","year":"2022","unstructured":"Schaafsma E, Takacs EM, Kaur S, Cheng C, Kurokawa M. Predicting clinical outcomes of cancer patients with a p53 deficiency gene signature. Sci Rep. 2022;12:1317.","journal-title":"Sci Rep"},{"key":"907_CR101","doi-asserted-by":"publisher","first-page":"595187","DOI":"10.3389\/fonc.2020.595187","volume":"10","author":"G Zhu","year":"2020","unstructured":"Zhu G, Pan C, Bei JX, Li B, Liang C, Xu Y, et al. Mutant p53 in Cancer Progression and Targeted Therapies. Front Oncol. 2020;10:595187.","journal-title":"Front Oncol"},{"key":"907_CR102","doi-asserted-by":"publisher","first-page":"1148389","DOI":"10.3389\/fmolb.2023.1148389","volume":"10","author":"L Carlsen","year":"2023","unstructured":"Carlsen L, Zhang S, Tian X, De La Cruz A, George A, Arnoff TE, et al. The role of p53 in anti-tumor immunity and response to immunotherapy. Front Mol Biosci. 2023;10:1148389.","journal-title":"Front Mol Biosci"},{"key":"907_CR103","doi-asserted-by":"crossref","unstructured":"Duffy MJ, Tang M, Rajaram S, O\u2019Grady S, Crown J. Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use? Cancers (Basel) 2022;14.","DOI":"10.3390\/cancers14184499"},{"key":"907_CR104","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2020.02.032","volume":"478","author":"MD Wilkie","year":"2020","unstructured":"Wilkie MD, Anaam EA, Lau AS, Rubbi CP, Jones TM, Boyd MT, et al. TP53 mutations in head and neck cancer cells determine the Warburg phenotypic switch creating metabolic vulnerabilities and therapeutic opportunities for stratified therapies. Cancer Lett. 2020;478:107\u201321.","journal-title":"Cancer Lett"},{"key":"907_CR105","doi-asserted-by":"crossref","unstructured":"Lu Y, Wu M, Xu Y, Yu L. The Development of p53-Targeted Therapies for Human Cancers. Cancers (Basel) 2023;15.","DOI":"10.3390\/cancers15143560"},{"key":"907_CR106","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas N","year":"2012","unstructured":"Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370.","journal-title":"Nature"},{"key":"907_CR107","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41418-022-00976-3","volume":"29","author":"KC de Andrade","year":"2022","unstructured":"de Andrade KC, Lee EE, Tookmanian EM, Kesserwan CA, Manfredi JJ, Hatton JN, et al. The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute. Cell Death Differ. 2022;29:1071\u20133.","journal-title":"Cell Death Differ"},{"key":"907_CR108","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41388-024-03219-6","volume":"44","author":"T Chen","year":"2025","unstructured":"Chen T, Ashwood LM, Kondrashova O, Strasser A, Kelly G, Sutherland KD. Breathing new insights into the role of mutant p53 in lung cancer. Oncogene. 2025;44:115\u201329.","journal-title":"Oncogene"},{"key":"907_CR109","doi-asserted-by":"crossref","unstructured":"Tracewell MA, Karlin JE, Barnada SM, McDuffie EL, Scott CP, Barta JA et al. Somatic p53 mutations that are markedly overrepresented in lung cancer confer resistance to reactive oxygen species-induced cell death. Carcinogenesis 2025;46.","DOI":"10.1093\/carcin\/bgaf027"},{"key":"907_CR110","doi-asserted-by":"crossref","unstructured":"Jeong M, Kim KB. Recent Research on Role of p53 Family in Small-Cell Lung Cancer. Cancers (Basel) 2025;17.","DOI":"10.3390\/cancers17071110"},{"key":"907_CR111","doi-asserted-by":"publisher","first-page":"5777","DOI":"10.1158\/1078-0432.CCR-13-0351","volume":"19","author":"RS Warren","year":"2013","unstructured":"Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, et al. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013;19:5777\u201387.","journal-title":"Clin Cancer Res"},{"key":"907_CR112","doi-asserted-by":"crossref","unstructured":"Liebl MC, Hofmann TG. The Role of p53 Signaling in Colorectal Cancer. Cancers (Basel) 2021;13.","DOI":"10.3390\/cancers13092125"},{"key":"907_CR113","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/jmcb\/mjy075","volume":"11","author":"M Nakayama","year":"2019","unstructured":"Nakayama M, Oshima M. Mutant p53 in colon cancer. J Mol Cell Biol. 2019;11:267\u201376.","journal-title":"J Mol Cell Biol"},{"key":"907_CR114","doi-asserted-by":"crossref","unstructured":"Zhang Y, Dube C, Gibert M Jr., Cruickshanks N, Wang B, Coughlan M et al. The p53 Pathway in Glioblastoma. Cancers (Basel) 2018;10.","DOI":"10.3390\/cancers10090297"},{"key":"907_CR115","doi-asserted-by":"publisher","first-page":"6204","DOI":"10.18632\/oncotarget.27252","volume":"10","author":"AK Roshandel","year":"2019","unstructured":"Roshandel AK, Busch CM, Mullekom JV, Cuoco JA, Rogers CM, Apfel LS, et al. The predictive capability of immunohistochemistry and DNA sequencing for determining TP53 functional mutation status: a comparative study of 41 glioblastoma patients. Oncotarget. 2019;10:6204\u201318.","journal-title":"Oncotarget"},{"key":"907_CR116","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41418-018-0126-3","volume":"26","author":"SW Ham","year":"2019","unstructured":"Ham SW, Jeon HY, Jin X, Kim EJ, Kim JK, Shin YJ, et al. TP53 gain-of-function mutation promotes inflammation in glioblastoma. Cell Death Differ. 2019;26:409\u201325.","journal-title":"Cell Death Differ"},{"key":"907_CR117","doi-asserted-by":"crossref","unstructured":"Wallis B, Bowman KR, Lu P, Lim CS. The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer. Biomolecules 2023;13.","DOI":"10.3390\/biom13010159"},{"key":"907_CR118","doi-asserted-by":"publisher","first-page":"26191","DOI":"10.1038\/srep26191","volume":"6","author":"AJ Cole","year":"2016","unstructured":"Cole AJ, Dwight T, Gill AJ, Dickson KA, Zhu Y, Clarkson A, et al. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Sci Rep. 2016;6:26191.","journal-title":"Sci Rep"},{"key":"907_CR119","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41416-019-0654-8","volume":"122","author":"M Tuna","year":"2020","unstructured":"Tuna M, Ju Z, Yoshihara K, Amos CI, Tanyi JL, Mills GB. Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers. Br J Cancer. 2020;122:405\u201312.","journal-title":"Br J Cancer"},{"key":"907_CR120","doi-asserted-by":"crossref","unstructured":"Guha T, Malkin D. Inherited TP53 Mutations and the Li-Fraumeni Syndrome. Cold Spring Harb Perspect Med 2017;7.","DOI":"10.1101\/cshperspect.a026187"},{"key":"907_CR121","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","volume":"28","author":"T Frebourg","year":"2020","unstructured":"Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R, Evans DG. European Reference Network G. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 2020;28:1379\u201386.","journal-title":"Eur J Hum Genet"},{"key":"907_CR122","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/BF01220804","volume":"122","author":"M Hamada","year":"1996","unstructured":"Hamada M, Fujiwara T, Hizuta A, Gochi A, Naomoto Y, Takakura N, et al. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol. 1996;122:360\u20135.","journal-title":"J Cancer Res Clin Oncol"},{"key":"907_CR123","doi-asserted-by":"crossref","unstructured":"Zhang S, Carlsen L, Hernandez Borrero L, Seyhan AA, Tian X, El-Deiry WS. Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer. Biomolecules 2022;12.","DOI":"10.20944\/preprints202201.0020.v1"},{"key":"907_CR124","doi-asserted-by":"publisher","first-page":"903075","DOI":"10.3389\/fmolb.2022.903075","volume":"9","author":"M Babamohamadi","year":"2022","unstructured":"Babamohamadi M, Babaei E, Ahmed Salih B, Babamohammadi M, Jalal Azeez H, Othman G. Recent findings on the role of wild-type and mutant p53 in cancer development and therapy. Front Mol Biosci. 2022;9:903075.","journal-title":"Front Mol Biosci"},{"key":"907_CR125","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","volume":"23","author":"ZY Dong","year":"2017","unstructured":"Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z, Liu SY, et al. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017;23:3012\u201324.","journal-title":"Clin Cancer Res"},{"key":"907_CR126","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018;8:822\u201335.","journal-title":"Cancer Discov"},{"key":"907_CR127","doi-asserted-by":"publisher","first-page":"217614","DOI":"10.1016\/j.canlet.2025.217614","volume":"617","author":"HH Wu","year":"2025","unstructured":"Wu HH, Leng S, Eisenstat DD, Sergi C, Leng R. Targeting p53 for immune modulation: Exploring its functions in tumor immunity and inflammation. Cancer Lett. 2025;617:217614.","journal-title":"Cancer Lett"},{"key":"907_CR128","doi-asserted-by":"crossref","unstructured":"Blagih J, Buck MD, Vousden KH. p53, cancer and the immune response. J Cell Sci 2020;133.","DOI":"10.1242\/jcs.237453"},{"key":"907_CR129","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41467-018-03224-w","volume":"9","author":"T Cooks","year":"2018","unstructured":"Cooks T, Pateras IS, Jenkins LM, Patel KM, Robles AI, Morris J, et al. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat Commun. 2018;9:771.","journal-title":"Nat Commun"},{"key":"907_CR130","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/intimm\/dxw019","volume":"28","author":"N Riaz","year":"2016","unstructured":"Riaz N, Morris L, Havel JJ, Makarov V, Desrichard A, Chan TA. The role of neoantigens in response to immune checkpoint blockade. Int Immunol. 2016;28:411\u20139.","journal-title":"Int Immunol"},{"key":"907_CR131","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333\u20139.","journal-title":"Nature"},{"key":"907_CR132","doi-asserted-by":"publisher","first-page":"a001016","DOI":"10.1101\/cshperspect.a001016","volume":"2","author":"AI Robles","year":"2010","unstructured":"Robles AI, Harris CC. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol. 2010;2:a001016.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"907_CR133","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1586\/14737140.3.1.63","volume":"3","author":"RS Midgley","year":"2003","unstructured":"Midgley RS, Kerr DJ. Immunotherapy for colorectal cancer. Expert Rev Anticancer Ther. 2003;3:63\u201378.","journal-title":"Expert Rev Anticancer Ther"},{"key":"907_CR134","doi-asserted-by":"publisher","first-page":"698","DOI":"10.21037\/tcr.2016.11.74","volume":"5","author":"S Kogan","year":"2016","unstructured":"Kogan S, Carpizo D. Pharmacological targeting of mutant p53. Transl Cancer Res. 2016;5:698\u2013706.","journal-title":"Transl Cancer Res"},{"key":"907_CR135","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/S0959-8049(03)00454-4","volume":"39","author":"VJ Bykov","year":"2003","unstructured":"Bykov VJ, Selivanova G, Wiman KG. Small molecules that reactivate mutant p53. Eur J Cancer. 2003;39:1828\u201334.","journal-title":"Eur J Cancer"},{"key":"907_CR136","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/2159-8290.CD-22-0381","volume":"13","author":"KZ Guiley","year":"2023","unstructured":"Guiley KZ, Shokat KM. A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability. Cancer Discov. 2023;13:56\u201369.","journal-title":"Cancer Discov"},{"key":"907_CR137","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.1093\/nar\/gkt305","volume":"41","author":"X Liu","year":"2013","unstructured":"Liu X, Wilcken R, Joerger AC, Chuckowree IS, Amin J, Spencer J, et al. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res. 2013;41:6034\u201344.","journal-title":"Nucleic Acids Res"},{"key":"907_CR138","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1089\/hum.2005.16.1016","volume":"16","author":"Z Peng","year":"2005","unstructured":"Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther. 2005;16:1016\u201327.","journal-title":"Hum Gene Ther"},{"key":"907_CR139","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1089\/hum.2017.218","volume":"29","author":"WW Zhang","year":"2018","unstructured":"Zhang WW, Li L, Li D, Liu J, Li X, Li W, et al. The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic. Hum Gene Ther. 2018;29:160\u201379.","journal-title":"Hum Gene Ther"},{"key":"907_CR140","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1517\/14712598.6.8.823","volume":"6","author":"DI Gabrilovich","year":"2006","unstructured":"Gabrilovich DI. INGN 201 (Advexin): adenoviral p53 gene therapy for cancer. Expert Opin Biol Ther. 2006;6:823\u201332.","journal-title":"Expert Opin Biol Ther"},{"key":"907_CR141","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/sj.bjc.6600006","volume":"86","author":"S Ries","year":"2002","unstructured":"Ries S, Korn WM. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer. 2002;86:5\u201311.","journal-title":"Br J Cancer"},{"key":"907_CR142","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JCO.2001.19.2.289","volume":"19","author":"J Nemunaitis","year":"2001","unstructured":"Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001;19:289\u201398.","journal-title":"J Clin Oncol"},{"key":"907_CR143","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101\u201324.","journal-title":"Nat Rev Drug Discov"},{"key":"907_CR144","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-1-4939-1862-1_10","volume":"1239","author":"L Cong","year":"2015","unstructured":"Cong L, Zhang F. Genome engineering using CRISPR-Cas9 system. Methods Mol Biol. 2015;1239:197\u2013217.","journal-title":"Methods Mol Biol"},{"key":"907_CR145","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281\u2013308.","journal-title":"Nat Protoc"},{"key":"907_CR146","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood-2024-205937","volume":"144","author":"JO Mascarenhas","year":"2024","unstructured":"Mascarenhas JO, Bose P, Hou HA, Homenda W, Ross D, Mohan SR, et al. Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed\/Refractory Myelofibrosis. Blood. 2024;144:483\u20135.","journal-title":"Blood"},{"key":"907_CR147","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1182\/blood-2024-201642","volume":"144","author":"JO Mascarenhas","year":"2024","unstructured":"Mascarenhas JO, Popov VM, Mohan S, \u00d6zkurt ZN, Kiladjian JJ, Al-Ali HK, et al. Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed\/Refractory Myelofibrosis. Blood. 2024;144:1000\u20131.","journal-title":"Blood"},{"key":"907_CR148","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1073\/pnas.0507493103","volume":"103","author":"C Tovar","year":"2006","unstructured":"Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A. 2006;103:1888\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"907_CR149","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844\u20138.","journal-title":"Science"},{"key":"907_CR150","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1021\/ml4000657","volume":"4","author":"B Vu","year":"2013","unstructured":"Vu B, Wovkulich P, Pizzolato G, Lovey A, Ding Q, Jiang N, et al. Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development. ACS Med Chem Lett. 2013;4:466\u20139.","journal-title":"ACS Med Chem Lett"},{"key":"907_CR151","doi-asserted-by":"crossref","unstructured":"Huang Y, Li W, Zhou Y, Bai J, Li N, Su Z et al. Strategies for p53 Activation and Targeted Inhibitors of the p53-Mdm2\/MdmX Interaction. Cells 2025; 14.","DOI":"10.3390\/cells14080583"},{"key":"907_CR152","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2174\/138161211795222603","volume":"17","author":"H Shen","year":"2011","unstructured":"Shen H, Maki CG. Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des. 2011;17:560\u20138.","journal-title":"Curr Pharm Des"},{"key":"907_CR153","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.2147\/OTT.S172315","volume":"12","author":"A Khurana","year":"2019","unstructured":"Khurana A, Shafer DA. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388). Onco Targets Ther. 2019;12:2903\u201310.","journal-title":"Onco Targets Ther"},{"key":"907_CR154","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1200\/JCO.20.02341","volume":"39","author":"DA Sallman","year":"2021","unstructured":"Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, et al. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021;39:1584\u201394.","journal-title":"J Clin Oncol"},{"key":"907_CR155","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1158\/2159-8290.CD-24-1421","volume":"15","author":"AM Puzio-Kuter","year":"2025","unstructured":"Puzio-Kuter AM, Xu L, McBrayer MK, Dominique R, Li HH, Fahr BJ, et al. Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator. Cancer Discov. 2025;15:1159\u201379.","journal-title":"Cancer Discov"},{"key":"907_CR156","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-19-0096","volume":"25","author":"A Lindemann","year":"2019","unstructured":"Lindemann A, Patel AA, Silver NL, Tang L, Liu Z, Wang L, et al. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms. Clin Cancer Res. 2019;25:5650\u201362.","journal-title":"Clin Cancer Res"},{"key":"907_CR157","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1158\/1078-0432.CCR-18-0822","volume":"24","author":"X Yu","year":"2018","unstructured":"Yu X, Kogan S, Chen Y, Tsang AT, Withers T, Lin H, et al. Zinc Metallochaperones Reactivate Mutant p53 Using an ON\/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics. Clin Cancer Res. 2018;24:4505\u201317.","journal-title":"Clin Cancer Res"},{"key":"907_CR158","doi-asserted-by":"publisher","first-page":"40583","DOI":"10.1074\/jbc.M102817200","volume":"276","author":"Y Peng","year":"2001","unstructured":"Peng Y, Chen L, Li C, Lu W, Chen J. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem. 2001;276:40583\u201390.","journal-title":"J Biol Chem"},{"key":"907_CR159","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/1541-7786.MCR-10-0534","volume":"9","author":"D Li","year":"2011","unstructured":"Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F, et al. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res. 2011;9:577\u201388.","journal-title":"Mol Cancer Res"},{"key":"907_CR160","doi-asserted-by":"crossref","unstructured":"Youssef ME, Cavalu S, Hasan AM, Yahya G, Abd-Eldayem MA, Saber S. Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice. Int J Mol Sci 2023;24.","DOI":"10.3390\/ijms24055014"},{"key":"907_CR161","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1038\/s41418-025-01502-x","volume":"32","author":"T Isermann","year":"2025","unstructured":"Isermann T, Schneider KL, Wegwitz F, De Oliveira T, Conradi LC, Volk V, et al. Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition. Cell Death Differ. 2025;32:1734\u201349.","journal-title":"Cell Death Differ"},{"key":"907_CR162","doi-asserted-by":"publisher","first-page":"8621","DOI":"10.1523\/JNEUROSCI.5214-12.2013","volume":"33","author":"C Brochier","year":"2013","unstructured":"Brochier C, Dennis G, Rivieccio MA, McLaughlin K, Coppola G, Ratan RR, et al. Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons. J Neurosci. 2013;33:8621\u201332.","journal-title":"J Neurosci"},{"key":"907_CR163","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/sj.cdd.4401581","volume":"12","author":"S Roy","year":"2005","unstructured":"Roy S, Packman K, Jeffrey R, Tenniswood M. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ. 2005;12:482\u201391.","journal-title":"Cell Death Differ"},{"key":"907_CR164","doi-asserted-by":"publisher","first-page":"107057","DOI":"10.1016\/j.ejps.2025.107057","volume":"208","author":"N El Omari","year":"2025","unstructured":"El Omari N, Bakrim S, Elhrech H, Aanniz T, Balahbib A, Lee LH, et al. Clinical efficacy and mechanistic insights of FDA-approved HDAC inhibitors in the treatment of lymphoma. Eur J Pharm Sci. 2025;208:107057.","journal-title":"Eur J Pharm Sci"},{"key":"907_CR165","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13148-023-01531-8","volume":"15","author":"G Lu","year":"2023","unstructured":"Lu G, Jin S, Lin S, Gong Y, Zhang L, Yang J, et al. Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL). Clin Epigenetics. 2023;15:124.","journal-title":"Clin Epigenetics"},{"key":"907_CR166","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1158\/1078-0432.CCR-11-3144","volume":"18","author":"HM Prince","year":"2012","unstructured":"Prince HM, Dickinson M. Romidepsin for cutaneous T-cell lymphoma. Clin Cancer Res. 2012;18:3509\u201315.","journal-title":"Clin Cancer Res"},{"key":"907_CR167","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-021-01434-3","volume":"21","author":"X Li","year":"2022","unstructured":"Li X, Pu W, Zheng Q, Ai M, Chen S, Peng Y. Proteolysis-targeting chimeras (PROTACs) in cancer therapy. Mol Cancer. 2022;21:99.","journal-title":"Mol Cancer"},{"key":"907_CR168","doi-asserted-by":"publisher","first-page":"761080","DOI":"10.3389\/fcell.2022.761080","volume":"10","author":"MA Rahman","year":"2022","unstructured":"Rahman MA, Park MN, Rahman MH, Rashid MM, Islam R, Uddin MJ, et al. p53 Modulation of Autophagy Signaling in Cancer Therapies: Perspectives Mechanism and Therapeutic Targets. Front Cell Dev Biol. 2022;10:761080.","journal-title":"Front Cell Dev Biol"},{"key":"907_CR169","doi-asserted-by":"publisher","first-page":"607149","DOI":"10.3389\/fonc.2020.607149","volume":"10","author":"Y Shi","year":"2020","unstructured":"Shi Y, Norberg E, Vakifahmetoglu-Norberg H. Mutant p53 as a Regulator and Target of Autophagy. Front Oncol. 2020;10:607149.","journal-title":"Front Oncol"},{"key":"907_CR170","doi-asserted-by":"publisher","first-page":"e838","DOI":"10.1038\/cddis.2013.350","volume":"4","author":"X Sui","year":"2013","unstructured":"Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 2013;4:e838.","journal-title":"Cell Death Dis"},{"key":"907_CR171","doi-asserted-by":"publisher","first-page":"e29911","DOI":"10.4161\/mco.29911","volume":"1","author":"G Manic","year":"2014","unstructured":"Manic G, Obrist F, Kroemer G, Vitale I, Galluzzi L. Chloroquine and hydroxychloroquine for cancer therapy. Mol Cell Oncol. 2014;1:e29911.","journal-title":"Mol Cell Oncol"},{"key":"907_CR172","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.18632\/oncotarget.6555","volume":"7","author":"C Du","year":"2016","unstructured":"Du C, Wu H, Leng R. UBE4B targets phosphorylated p53 at serines 15 and 392 for degradation. Oncotarget. 2016;7:2823\u201336.","journal-title":"Oncotarget"},{"key":"907_CR173","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41420-025-02441-9","volume":"11","author":"Y Abuetabh","year":"2025","unstructured":"Abuetabh Y, Wu HH, Al Yousef H, Persad S, Schlosser MP, Eisenstat DD, et al. Deciphering UBE4B phosphorylation dynamics: a key mechanism in p53 accumulation and cancer cell response to DNA damage. Cell Death Discov. 2025;11:131.","journal-title":"Cell Death Discov"},{"key":"907_CR174","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ccr.2009.01.019","volume":"15","author":"M Enge","year":"2009","unstructured":"Enge M, Bao W, Hedstrom E, Jackson SP, Moumen A, Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell. 2009;15:171\u201383.","journal-title":"Cancer Cell"},{"key":"907_CR175","doi-asserted-by":"publisher","first-page":"e29065","DOI":"10.1002\/pbc.29065","volume":"68","author":"T Cash","year":"2021","unstructured":"Cash T, Fox E, Liu X, Minard CG, Reid JM, Scheck AC, et al. A phase 1 study of prexasertib (LY2606368), a CHK1\/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children\u2019s Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515). Pediatr Blood Cancer. 2021;68:e29065.","journal-title":"Pediatr Blood Cancer"},{"key":"907_CR176","doi-asserted-by":"publisher","first-page":"53377","DOI":"10.18632\/oncotarget.10535","volume":"7","author":"A Di Ghelli Luserna","year":"2016","unstructured":"Di Ghelli Luserna A, Iacobucci I, Imbrogno E, Papayannidis C, Derenzini E, Ferrari A, et al. Prexasertib, a Chk1\/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-\/T- cell progenitor acute lymphoblastic leukemia. Oncotarget. 2016;7:53377\u201391.","journal-title":"Oncotarget"},{"key":"907_CR177","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41389-019-0147-x","volume":"8","author":"AM van Harten","year":"2019","unstructured":"van Harten AM, Buijze M, van der Mast R, Rooimans MA, Martens-de Kemp SR, Bachas C, et al. Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death. Oncogenesis. 2019;8:38.","journal-title":"Oncogenesis"},{"key":"907_CR178","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41419-025-07435-0","volume":"16","author":"E Melia","year":"2025","unstructured":"Melia E, Fisch AS, Tinhofer I, Parsons JL. Targeting Chk1 and Wee1 kinases enhances radiosensitivity of 2D and 3D head and neck cancer models to X-rays and low\/high-LET protons. Cell Death Dis. 2025;16:128.","journal-title":"Cell Death Dis"},{"key":"907_CR179","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1021\/acsmedchemlett.2c00481","volume":"14","author":"S Guler","year":"2023","unstructured":"Guler S, DiPoto MC, Crespo A, Caldwell R, Doerfel B, Grossmann N, et al. Selective Wee1 Inhibitors Led to Antitumor Activity In Vitro and Correlated with Myelosuppression. ACS Med Chem Lett. 2023;14:566\u201376.","journal-title":"ACS Med Chem Lett"},{"key":"907_CR180","doi-asserted-by":"publisher","first-page":"eadu6989","DOI":"10.1126\/scitranslmed.adu6989","volume":"17","author":"X Jiao","year":"2025","unstructured":"Jiao X, Liu J, Wu Y, Zhong Q, Zhu L, Wang L, et al. Sequential treatment with PARPi and WEE1i enhances antitumor immune responses in preclinical models of ovarian cancer. Sci Transl Med. 2025;17:eadu6989.","journal-title":"Sci Transl Med"},{"key":"907_CR181","doi-asserted-by":"crossref","unstructured":"Williams AB, Schumacher B. p53 in the DNA-Damage-Repair Process. Cold Spring Harb Perspect Med 2016;6.","DOI":"10.1101\/cshperspect.a026070"},{"key":"907_CR182","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.gcb.2010.10.002","volume":"35","author":"S Emami","year":"2011","unstructured":"Emami S. Interplay between p53-family, their regulators, and PARPs in DNA repair. Clin Res Hepatol Gastroenterol. 2011;35:98\u2013104.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"907_CR183","doi-asserted-by":"publisher","first-page":"101434","DOI":"10.1016\/j.xcrm.2024.101434","volume":"5","author":"MM Alruwaili","year":"2024","unstructured":"Alruwaili MM, Zonneville J, Naranjo MN, Serio H, Melendy T, Straubinger RM, et al. A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers. Cell Rep Med. 2024;5:101434.","journal-title":"Cell Rep Med"},{"key":"907_CR184","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","volume":"16","author":"A Min","year":"2017","unstructured":"Min A, Im SA, Jang H, Kim S, Lee M, Kim DK, et al. AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells. Mol Cancer Ther. 2017;16:566\u201377.","journal-title":"Mol Cancer Ther"},{"key":"907_CR185","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41420-025-02418-8","volume":"11","author":"S Peng","year":"2025","unstructured":"Peng S, Long M, Chen Q, Yin Z, Zeng C, Zhang W, et al. Perspectives on cancer therapy-synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges. Cell Death Discov. 2025;11:179.","journal-title":"Cell Death Discov"},{"issue":"Suppl 1","key":"907_CR186","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/S0140-6736(15)60373-7","volume":"385","author":"M Kwok","year":"2015","unstructured":"Kwok M, Davies N, Agathanggelou A, Smith E, Petermann E, Yates E, et al. Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway. Lancet. 2015;385(Suppl 1):S58.","journal-title":"Lancet"},{"key":"907_CR187","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1038\/onc.2016.360","volume":"36","author":"TQ Tran","year":"2017","unstructured":"Tran TQ, Lowman XH, Reid MA, Mendez-Dorantes C, Pan M, Yang Y, et al. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction. Oncogene. 2017;36:1991\u20132001.","journal-title":"Oncogene"},{"key":"907_CR188","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s12276-023-00971-9","volume":"55","author":"J Jin","year":"2023","unstructured":"Jin J, Byun JK, Choi YK, Park KG. Targeting glutamine metabolism as a therapeutic strategy for cancer. Exp Mol Med. 2023;55:706\u201315.","journal-title":"Exp Mol Med"},{"key":"907_CR189","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1038\/s41467-023-42458-1","volume":"14","author":"C Tombari","year":"2023","unstructured":"Tombari C, Zannini A, Bertolio R, Pedretti S, Audano M, Triboli L, et al. Mutant p53 sustains serine-glycine synthesis and essential amino acids intake promoting breast cancer growth. Nat Commun. 2023;14:6777.","journal-title":"Nat Commun"},{"key":"907_CR190","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","volume":"14","author":"EE Manasanch","year":"2017","unstructured":"Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017;14:417\u201333.","journal-title":"Nat Rev Clin Oncol"},{"key":"907_CR191","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4049\/jimmunol.2300212","volume":"212","author":"TA Ochoa","year":"2024","unstructured":"Ochoa TA, Rossi A, Woodle ES, Hildeman D, Allman D. The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells. J Immunol. 2024;212:154\u201364.","journal-title":"J Immunol"},{"key":"907_CR192","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1158\/0008-5472.CAN-18-3744","volume":"79","author":"Y Xue","year":"2019","unstructured":"Xue Y, Barker N, Hoon S, He P, Thakur T, Abdeen SR, et al. Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of Both Normal and Tumor Tissues In Vivo. Cancer Res. 2019;79:3595\u2013607.","journal-title":"Cancer Res"},{"key":"907_CR193","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canlet.2017.04.038","volume":"401","author":"B Wang","year":"2017","unstructured":"Wang B, Wu H, Chai C, Lewis J, Pichiorri F, Eisenstat DD, et al. MicroRNA-1301 suppresses tumor cell migration and invasion by targeting the p53\/UBE4B pathway in multiple human cancer cells. Cancer Lett. 2017;401:20\u201332.","journal-title":"Cancer Lett"},{"key":"907_CR194","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrm2147","volume":"8","author":"KH Vousden","year":"2007","unstructured":"Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8:275\u201383.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"907_CR195","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","volume":"170","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell. 2017;170:1062\u201378.","journal-title":"Cell"},{"key":"907_CR196","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1016\/j.celrep.2019.08.061","volume":"28","author":"LA Donehower","year":"2019","unstructured":"Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, et al. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Cell Rep. 2019;28:3010.","journal-title":"Cell Rep"},{"key":"907_CR197","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev-biochem-060815-014710","volume":"85","author":"AC Joerger","year":"2016","unstructured":"Joerger AC, Fersht AR. The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches. Annu Rev Biochem. 2016;85:375\u2013404.","journal-title":"Annu Rev Biochem"},{"key":"907_CR198","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.1092734","volume":"303","author":"JE Chipuk","year":"2004","unstructured":"Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303:1010\u20134.","journal-title":"Science"},{"key":"907_CR199","doi-asserted-by":"publisher","first-page":"7486","DOI":"10.1038\/sj.onc.1206949","volume":"22","author":"WS El-Deiry","year":"2003","unstructured":"El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene. 2003;22:7486\u201395.","journal-title":"Oncogene"},{"key":"907_CR200","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S0092-8674(00)00171-9","volume":"103","author":"KH Vousden","year":"2000","unstructured":"Vousden KH. p53: death star. Cell. 2000;103:691\u20134.","journal-title":"Cell"},{"key":"907_CR201","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrc883","volume":"2","author":"S Cory","year":"2002","unstructured":"Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2:647\u201356.","journal-title":"Nat Rev Cancer"},{"key":"907_CR202","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/nrd2658","volume":"7","author":"G Lessene","year":"2008","unstructured":"Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008;7:989\u20131000.","journal-title":"Nat Rev Drug Discov"},{"key":"907_CR203","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1126\/science.288.5468.1053","volume":"288","author":"E Oda","year":"2000","unstructured":"Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288:1053\u20138.","journal-title":"Science"},{"issue":"Suppl 1","key":"907_CR204","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1038\/onc.2009.45","volume":"27","author":"J Yu","year":"2008","unstructured":"Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene. 2008;27(Suppl 1):S71\u201383.","journal-title":"Oncogene"},{"key":"907_CR205","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016;374:311\u201322.","journal-title":"N Engl J Med"},{"key":"907_CR206","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/cdd.2015.50","volume":"22","author":"AR Delbridge","year":"2015","unstructured":"Delbridge AR, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 2015;22:1071\u201380.","journal-title":"Cell Death Differ"},{"key":"907_CR207","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.cytogfr.2008.04.001","volume":"19","author":"A Ashkenazi","year":"2008","unstructured":"Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008;19:325\u201331.","journal-title":"Cytokine Growth Factor Rev"},{"key":"907_CR208","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/cdd.2014.81","volume":"21","author":"J Lemke","year":"2014","unstructured":"Lemke J, von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ. 2014;21:1350\u201364.","journal-title":"Cell Death Differ"},{"key":"907_CR209","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019;380:2225\u201336.","journal-title":"N Engl J Med"},{"key":"907_CR210","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S, et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018;378:1107\u201320.","journal-title":"N Engl J Med"},{"key":"907_CR211","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768\u201378.","journal-title":"Lancet Oncol"},{"key":"907_CR212","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nrc821","volume":"2","author":"A Ashkenazi","year":"2002","unstructured":"Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2:420\u201330.","journal-title":"Nat Rev Cancer"},{"key":"907_CR213","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.coph.2004.02.006","volume":"4","author":"SK Kelley","year":"2004","unstructured":"Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L\/TRAIL. Curr Opin Pharmacol. 2004;4:333\u20139.","journal-title":"Curr Opin Pharmacol"},{"key":"907_CR214","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00262-011-1008-4","volume":"60","author":"TJ Sayers","year":"2011","unstructured":"Sayers TJ. Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother. 2011;60:1173\u201380.","journal-title":"Cancer Immunol Immunother"},{"key":"907_CR215","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/0092-8674(93)90500-P","volume":"75","author":"WS el-Deiry","year":"1993","unstructured":"el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817\u201325.","journal-title":"Cell"},{"key":"907_CR216","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/0092-8674(93)90499-G","volume":"75","author":"JW Harper","year":"1993","unstructured":"Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805\u201316.","journal-title":"Cell"},{"key":"907_CR217","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153\u201366.","journal-title":"Nat Rev Cancer"},{"key":"907_CR218","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S1535-6108(02)00102-2","volume":"2","author":"CJ Sherr","year":"2002","unstructured":"Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002;2:103\u201312.","journal-title":"Cancer Cell"},{"key":"907_CR219","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25\u201335.","journal-title":"Lancet Oncol"},{"key":"907_CR220","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O\u2019Leary","year":"2016","unstructured":"O\u2019Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4\/6 inhibitors. Nat Rev Clin Oncol. 2016;13:417\u201330.","journal-title":"Nat Rev Clin Oncol"},{"key":"907_CR221","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375:1925\u201336.","journal-title":"N Engl J Med"},{"key":"907_CR222","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1080\/15384101.2018.1502567","volume":"17","author":"KL Thu","year":"2018","unstructured":"Thu KL, Soria-Bretones I, Mak TW, Cescon DW. Targeting the cell cycle in breast cancer: towards the next phase. Cell Cycle. 2018;17:1871\u201385.","journal-title":"Cell Cycle"},{"key":"907_CR223","doi-asserted-by":"crossref","unstructured":"Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y et al. PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst 2016;108.","DOI":"10.1093\/jnci\/djv303"},{"key":"907_CR224","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s41467-017-01117-y","volume":"8","author":"H Rahnamoun","year":"2017","unstructured":"Rahnamoun H, Lu H, Duttke SH, Benner C, Glass CK, Lauberth SM. Mutant p53 shapes the enhancer landscape of cancer cells in response to chronic immune signaling. Nat Commun. 2017;8:754.","journal-title":"Nat Commun"},{"key":"907_CR225","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124\u20138.","journal-title":"Science"},{"key":"907_CR226","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.lungcan.2019.04.005","volume":"132","author":"S Assoun","year":"2019","unstructured":"Assoun S, Theou-Anton N, Nguenang M, Cazes A, Danel C, Abbar B, et al. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. Lung Cancer. 2019;132:65\u201371.","journal-title":"Lung Cancer"},{"key":"907_CR227","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1158\/1078-0432.CCR-18-0163","volume":"TP53","author":"J Biton","year":"2018","unstructured":"Biton J, Mansuet-Lupo A, Pecuchet N, Alifano M, Ouakrim H, Arrondeau J, et al. STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. Clin Cancer Res. 2018;TP53:24: 5710\u201323.","journal-title":"Clin Cancer Res"},{"key":"907_CR228","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","volume":"39","author":"M Ghosh","year":"2021","unstructured":"Ghosh M, Saha S, Bettke J, Nagar R, Parrales A, Iwakuma T, et al. Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell. 2021;39:494\u2013508. e495.","journal-title":"Cancer Cell"},{"key":"907_CR229","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.7150\/ijbs.67200","volume":"18","author":"N Liu","year":"2022","unstructured":"Liu N, Jiang X, Guo L, Zhang C, Jiang M, Sun Z, et al. Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2\/AKT\/PD-L1 pathway. Int J Biol Sci. 2022;18:2419\u201338.","journal-title":"Int J Biol Sci"},{"key":"907_CR230","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1038\/s41416-022-01971-8","volume":"127","author":"X Zhou","year":"2022","unstructured":"Zhou X, Santos GS, Zhan Y, Oliveira MMS, Rezaei S, Singh M, et al. Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246. Br J Cancer. 2022;127:2060\u201371.","journal-title":"Br J Cancer"},{"key":"907_CR231","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1126\/science.7521539","volume":"265","author":"KM Dameron","year":"1994","unstructured":"Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994;265:1582\u20134.","journal-title":"Science"},{"key":"907_CR232","first-page":"6161","volume":"55","author":"D Mukhopadhyay","year":"1995","unstructured":"Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 1995;55:6161\u20135.","journal-title":"Cancer Res"},{"key":"907_CR233","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1101\/gad.14.1.34","volume":"14","author":"R Ravi","year":"2000","unstructured":"Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000;14:34\u201344.","journal-title":"Genes Dev"},{"key":"907_CR234","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nsmb.1669","volume":"16","author":"G Fontemaggi","year":"2009","unstructured":"Fontemaggi G, Dell\u2019Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, et al. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol. 2009;16:1086\u201393.","journal-title":"Nat Struct Mol Biol"},{"key":"907_CR235","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00109-007-0221-2","volume":"85","author":"JG Teodoro","year":"2007","unstructured":"Teodoro JG, Evans SK, Green MR. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med (Berl). 2007;85:1175\u201386.","journal-title":"J Mol Med (Berl)"},{"key":"907_CR236","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1158\/0008-5472.CAN-14-2305","volume":"75","author":"M Schwaederle","year":"2015","unstructured":"Schwaederle M, Lazar V, Validire P, Hansson J, Lacroix L, Soria JC, et al. VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy. Cancer Res. 2015;75:1187\u201390.","journal-title":"Cancer Res"},{"key":"907_CR237","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1200\/JCO.21.02506","volume":"40","author":"KW Thiel","year":"2022","unstructured":"Thiel KW, Devor EJ, Filiaci VL, Mutch D, Moxley K, Alvarez Secord A, et al. TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology\/Gynecologic Oncology Group Study. J Clin Oncol. 2022;40:3289\u2013300.","journal-title":"J Clin Oncol"},{"key":"907_CR238","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1158\/1535-7163.MCT-16-0196","volume":"15","author":"JJ Wheler","year":"2016","unstructured":"Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, et al. TP53 Alterations Correlate with Response to VEGF\/VEGFR Inhibitors: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016;15:2475\u201385.","journal-title":"Mol Cancer Ther"},{"key":"907_CR239","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","volume":"20","author":"AJ Levine","year":"2020","unstructured":"Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20:471\u201380.","journal-title":"Nat Rev Cancer"},{"key":"907_CR240","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ccr.2007.10.001","volume":"12","author":"T Soussi","year":"2007","unstructured":"Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell. 2007;12:303\u201312.","journal-title":"Cancer Cell"},{"key":"907_CR241","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/0092-8674(93)90719-7","volume":"74","author":"SW Lowe","year":"1993","unstructured":"Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957\u201367.","journal-title":"Cell"},{"key":"907_CR242","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1038\/onc.2012.610","volume":"32","author":"JG Jackson","year":"2013","unstructured":"Jackson JG, Lozano G. The mutant p53 mouse as a pre-clinical model. Oncogene. 2013;32:4325\u201330.","journal-title":"Oncogene"},{"key":"907_CR243","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1021\/acsmedchemlett.4c00379","volume":"16","author":"BT Vu","year":"2025","unstructured":"Vu BT, Dominique R, Fahr BJ, Li HH, Fry DC, Xu L, et al. Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development. ACS Med Chem Lett. 2025;16:34\u20139.","journal-title":"ACS Med Chem Lett"},{"key":"907_CR244","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018;378:2093\u2013104.","journal-title":"N Engl J Med"},{"key":"907_CR245","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913\u20137.","journal-title":"Nature"},{"key":"907_CR246","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917\u201321.","journal-title":"Nature"},{"key":"907_CR247","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017;355:1152\u20138.","journal-title":"Science"},{"key":"907_CR248","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ejca.2017.06.023","volume":"83","author":"MJ Duffy","year":"2017","unstructured":"Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017;83:258\u201365.","journal-title":"Eur J Cancer"},{"key":"907_CR249","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrd4236","volume":"13","author":"KH Khoo","year":"2014","unstructured":"Khoo KH, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014;13:217\u201336.","journal-title":"Nat Rev Drug Discov"},{"key":"907_CR250","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrclinonc.2017.151","volume":"15","author":"K Sabapathy","year":"2018","unstructured":"Sabapathy K, Lane DP. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat Rev Clin Oncol. 2018;15:13\u201330.","journal-title":"Nat Rev Clin Oncol"},{"key":"907_CR251","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s11658-021-00293-6","volume":"26","author":"L Haronikova","year":"2021","unstructured":"Haronikova L, Bonczek O, Zatloukalova P, Kokas-Zavadil F, Kucerikova M, Coates PJ, et al. Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them? Cell Mol Biol Lett. 2021;26:53.","journal-title":"Cell Mol Biol Lett"},{"key":"907_CR252","doi-asserted-by":"publisher","first-page":"E5271","DOI":"10.1073\/pnas.1610421113","volume":"113","author":"MR Bauer","year":"2016","unstructured":"Bauer MR, Joerger AC, Fersht AR. 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells. Proc Natl Acad Sci U S A. 2016;113:E5271\u20135280.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"907_CR253","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1016\/j.febslet.2014.04.017","volume":"588","author":"VJ Bykov","year":"2014","unstructured":"Bykov VJ, Wiman KG. Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett. 2014;588:2622\u20137.","journal-title":"FEBS Lett"},{"key":"907_CR254","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1158\/2159-8290.CD-20-1741","volume":"11","author":"X Zhou","year":"2021","unstructured":"Zhou X, Singh M, Sanz Santos G, Guerlavais V, Carvajal LA, Aivado M, et al. Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity. Cancer Discov. 2021;11:3090\u2013105.","journal-title":"Cancer Discov"},{"key":"907_CR255","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","volume":"25","author":"CA Lino","year":"2018","unstructured":"Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv. 2018;25:1234\u201357.","journal-title":"Drug Deliv"},{"key":"907_CR256","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.bbrc.2014.07.014","volume":"450","author":"S Zhen","year":"2014","unstructured":"Zhen S, Hua L, Takahashi Y, Narita S, Liu YH, Li Y. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR\/Cas9. Biochem Biophys Res Commun. 2014;450:1422\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"907_CR257","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1200\/JCO.2016.67.5942","volume":"34","author":"S Leijen","year":"2016","unstructured":"Leijen S, van Geel RM, Sonke GS, de Jong D, Rosenberg EH, Marchetti S, et al. Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. J Clin Oncol. 2016;34:4354\u201361.","journal-title":"J Clin Oncol"},{"key":"907_CR258","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","volume":"60","author":"MJ O\u2019Connor","year":"2015","unstructured":"O\u2019Connor MJ. Targeting the DNA Damage Response in Cancer. Mol Cell. 2015;60:547\u201360.","journal-title":"Mol Cell"},{"key":"907_CR259","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583\u20139.","journal-title":"Nature"},{"key":"907_CR260","doi-asserted-by":"publisher","first-page":"870","DOI":"10.2174\/1567201821666230905090621","volume":"21","author":"V Sharma","year":"2024","unstructured":"Sharma V, Singh A, Chauhan S, Sharma PK, Chaudhary S, Sharma A, et al. Role of Artificial Intelligence in Drug Discovery and Target Identification in Cancer. Curr Drug Deliv. 2024;21:870\u201386.","journal-title":"Curr Drug Deliv"},{"key":"907_CR261","unstructured":"Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol 2017; 2017."},{"key":"907_CR262","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jama.2017.11137","volume":"318","author":"D Mandelker","year":"2017","unstructured":"Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, et al. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA. 2017;318:825\u201335.","journal-title":"JAMA"},{"key":"907_CR263","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/sj.onc.1202314","volume":"18","author":"G Blandino","year":"1999","unstructured":"Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene. 1999;18:477\u201385.","journal-title":"Oncogene"},{"key":"907_CR264","doi-asserted-by":"publisher","first-page":"1258096","DOI":"10.1126\/science.1258096","volume":"346","author":"JA Doudna","year":"2014","unstructured":"Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346:1258096.","journal-title":"Science"},{"key":"907_CR265","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bbamcr.2013.05.022","volume":"1843","author":"AK Hock","year":"2014","unstructured":"Hock AK, Vousden KH. The role of ubiquitin modification in the regulation of p53. Biochim Biophys Acta. 2014;1843:137\u201349.","journal-title":"Biochim Biophys Acta"},{"key":"907_CR266","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/cdd.2009.68","volume":"17","author":"JC Marine","year":"2010","unstructured":"Marine JC, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ. 2010;17:93\u2013102.","journal-title":"Cell Death Differ"},{"key":"907_CR267","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrc3430","volume":"13","author":"M Wade","year":"2013","unstructured":"Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13:83\u201396.","journal-title":"Nat Rev Cancer"}],"container-title":["Cellular & Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-026-00907-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-026-00907-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-026-00907-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:04:45Z","timestamp":1781834685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11658-026-00907-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":267,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["907"],"URL":"https:\/\/doi.org\/10.1186\/s11658-026-00907-x","relation":{},"ISSN":["1689-1392"],"issn-type":[{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final version of the manuscript and its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}